Table 4.
Selected characteristics of adults with advanced HIV admitted to hospital within 1 year of enrollment, cross-referenced with research-assigned cause of first admission (N = 251)
| Characteristic | Total, n (%) or median (IQR) | Research cause assigned to first admission, n (column %) or median (IQR) | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| AIDS-related | Previously undiagnosed TB | Worsening TB on TB treatment | Surgical | Treatment related | Bacterial infection | Gastrointestinal | Hepatic/renal failure | Other | ||
| Total | 251 | 41 | 52 | 43 | 21 | 18 | 20 | 12 | 9 | 35 |
| Age group (y) | ||||||||||
| 18–23 | 6 (2.4) | 2 (4.9) | 1 (1.9) | 2 (4.7) | 1 (4.8) | 0 | 0 | 0 | 0 | 0 |
| 24–33 | 70 (27.9) | 9 (22.0) | 21 (40.4) | 11 (25.6) | 7 (33.3) | 7 (38.9) | 2(10.0) | 5 (41.7) | 1 (11.1) | 7 (20.0) |
| 34–43 | 106 (42.2) | 17 (41.5) | 24 (46.2) | 15 (34.9) | 10 (47.6) | 7 (38.9) | 8 (40.0) | 3 (25.0) | 4 (44.4) | 18 (51.4) |
| 44–60 | 61 (24.3) | 10 (24.4) | 6 (11.5) | 14 (32.6) | 3 (14.3) | 4 (22.2) | 9 (45.0) | 4 (33.3) | 3 (33.3) | 8 (22.9) |
| > 60 | 8 (3.2) | 3 (7.3) | 0 | 1 (2.3) | 0 | 0 | 1 | 0 | 1 (11.1) | 2 (5.7) |
| Female | 130 (51.8) | 21 (51.2) | 27 (51.9) | 18 (41.9) | 17 (81.0) | 12 (66.7) | 8 (40.0) | 4 (33.3) | 4 (44.4.) | 19 (54.3) |
| Enrolled in intervention arm of TB Fast Track trial | 145 (57.8) | 29 (70.7) | 16 (30.8) | 30(69.8) | 14 (66.7) | 12 (66.7) | 11 (55.0) | 7 (58.3) | 3 (33.3) | 23 (65.7) |
| CD4 count at enrollment to TB Fast Track trial (cells/µL) | ||||||||||
| ≤50 | 132 (52.6) | 27 (65.9) | 31 (59.6) | 25 (58.1) | 6 (28.6) | 11 (61.1) | 5 (25.0) | 6 (50.0) | 3 (33.3) | 18 (51.4) |
| 51–100 | 80 (31.9) | 11 (26.8) | 10 (19.2) | 13 (30.2) | 9 (42.9) | 4 (22.2) | 11 (55.0) | 4 (33.3) | 5 (55.6) | 13 (37.1) |
| 101–150 | 39 (15.5) | 3 (7.3) | 11 (21.2) | 5 (11.6) | 6 (28.6) | 3 (16.7) | 4 (20.0) | 2 (16.7) | 1 (11.1) | 4 (11.4) |
| Time from enrollment to admission (d) | ||||||||||
| ≤ 7 | 30 (12.0) | 6 (14.6) | 9 (17.3) | 8 (18.6) | 0 | 0 | 0 | 0 | 0 | 7 (20.0) |
| 8–28 | 69 (27.5) | 19 (46.3) | 13 (25.0) | 8 (18.6) | 5 (23.8) | 9 (50.0) | 5 (25.0) | 2 (16.7) | 1 (11.1) | 7 (20.0) |
| 29–90 | 76 (30.3) | 7 (17.1) | 21 (40.4) | 11 (25.6) | 5 (23.8) | 6 (33.3) | 5 (25.0) | 3 (25.0) | 4 (44.4) | 14 (40.0) |
| 91–180 | 51 (20.3) | 4 (9.8) | 7 (13.5) | 11 (25.6) | 8 (38.1) | 2 (11.1) | 8 (40.0) | 4 (33.3) | 2 (22.2) | 5 (14.3) |
| 181–365 | 25 (10.0) | 5 (12.2) | 2 (3.9) | 5 (11.6) | 3 (14.3) | 1 (5.6) | 2(10.0) | 3 (25.0) | 2 (22.2) | 2 (5.7) |
| On ART at admission | 152 (60.6) | 17 (41.5) | 34 (65.4) | 26 (60.5) | 17 (81.0) | 9 (50.0) | 13 (65.0) | 10 (83.3.) | 6 (66.7) | 20 (57.1) |
| On TB treatment at admission | 126 (50.2) | 20 (48.8) | 0 | 43 (100) | 8 (38.1) | 16 (88.9) | 10 (50.0) | 6 (50.0) | 3 (33.3) | 20 (57.1) |
| Creatinine and eGFR measured at admission | 206 | 37 | 45 | 37 | 14 | 14 | 17 | 7 | 9 | 26 |
| Creatinine level at admission (µmol/L) | 88 (65–226) | 77 (65–114) | 105 (75–264) | 88 (65–189) | 74 (56–98) | 93 (68–134) | 106 (68–503) | 118 (63–393) | 1,324 (1,018– 1,606) | 75 (58–100) |
| eGFR at admission (mL/min/1.73 m2) | ||||||||||
| ≤ 30 | 60 (29.1) | 8 (21.6) | 14 (31.1) | 11 (29.7) | 2 (14.3) | 3 (21.4) | 7 (41.2) | 3 (42.9) | 9 (100.0) | 3 (11.5) |
| 31–60 | 25 (12.1) | 3 (8.1) | 8 (17.8) | 4 (10.8) | 2 (14.3) | 3 (21.4) | 2 (11.7) | 1 (14.3) | 0 | 2 (7.7) |
| 61–90 | 37 (18.0) | 6 (16.2) | 9 (20.0) | 6 (16.2) | 4 (28.6) | 3 (21.4) | 3 (17.6) | 1 (14.3) | 0 | 5 (19.2) |
| > 90 | 84 (40.8) | 20 (54.1) | 14 (31.1) | 16 (43.2) | 6 (42.9) | 5 (35.7) | 5 (29.4) | 2 (28.6) | 0 | 16 (61.5) |
| Hb measured at admission | 223 | 35 | 49 | 40 | 17 | 16 | 17 | 11 | 9 | 29 |
| Hb at admission (g/dL) | ||||||||||
| < 7.0 | 51 (22.8) | 5 (14.3) | 15 (30.6) | 6 (15.0) | 2 (11.8) | 1 (6.3) | 8 (47.1) | 1 (9.1) | 4 (44.4) | 9 (31.0) |
| 7.0–8.9 | 50 (22.4) | 8 (22.9) | 12 (24.5) | 13 (32.5) | 3 (17.7) | 1 (6.3) | 5 (29.4) | 3 (27.3) | 3 (33.3) | 2 (6.9) |
| 9.0–10.9 | 56 (25.1) | 9 (25.7) | 9 (18.4) | 11(27.5) | 4 (23.5) | 6 (37.5) | 4 (23.5) | 3 (27.3) | 1 (11.1) | 9 (31.0) |
| 11.0–12.9 | 47 (21.1) | 12 (34.3) | 8 (16.3) | 9 (22.5) | 6 (35.3) | 6 (37.5) | 0 | 2 (18.2) | 1 (11.1) | 3 (10.3) |
| ≥ 13.0 | 19 (8.5) | 1 | 5 (10.2) | 1 (2.5) | 2 (11.8) | 2 (12.5) | 0 | 2 (18.2) | 0 | 6 (20.7) |
ART = antiretroviral therapy; eGFR = estimated glomerular filtration rate; Hb = hemoglobin; IQR = interquartile range; TB = tuberculosis.